Skip to content

FDA OKs Novartis’ ofatumumab for multiple sclerosis

August 20, 2020

The FDA approves Novartis’ (NVS +1.4%) Kesimpta (ofatumumab) for the treatment of relapsing forms of multiple sclerosis (MS).

The company expects the nod in Europe by Q2 2021.

The company markets the CD20-directed cytolytic antibody as Arzerra for chronic lymphocytic leukemia.

It was discovered by Genmab A/S (GMAB +1.9%) who licensed the rights to GlaxoSmithKline (GSK -0.5%) in 2006. Novartis acquired the rights in the autoimmune space from GSK in December 2015.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: